Compare SIM & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIM | BLLN |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.4B |
| IPO Year | 2002 | 2025 |
| Metric | SIM | BLLN |
|---|---|---|
| Price | $26.40 | $100.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $126.71 |
| AVG Volume (30 Days) | 549.0 | ★ 540.5K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | ★ $305,112,000.00 |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | N/A | $30.14 |
| P/E Ratio | ★ $32.88 | $205.77 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $25.20 | $61.96 |
| 52 Week High | $34.59 | $150.44 |
| Indicator | SIM | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 46.33 |
| Support Level | $26.38 | $88.85 |
| Resistance Level | $27.45 | $101.62 |
| Average True Range (ATR) | 0.33 | 4.58 |
| MACD | -0.37 | 1.42 |
| Stochastic Oscillator | 0.00 | 65.11 |
Grupo Simec SAB de CV is a diversified producer, processor and distributor of SBQ steel and structural steel products with production and commercial operations. The group's SBQ products are used across a range of engineered end-user applications, including axles, hubs, and crankshafts for automobiles and light trucks, machine tools, and off-highway equipment. Its structural steel products are used in the non-residential construction market and other construction applications. Its segments are Mexico, Brazil, and the United States of America. The maximum of its sales is from the Mexico segment.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.